We appreciate the interest of H.M. Dodds and L.P. Rivory in our study on the mechanisms related to the acute cholinergic eects of irinotecan (Blandizzi et al., Br. J. Pharmacol., 132: 73 ± 84, 2001 ). However, despite the eorts made to reproduce our experiments on the in vitro acetylcholinesterase (AChE) assay, we note that these authors still fail to propose any convincing explanation accounting for the discrepancy between our data (Blandizzi et al., 2001) and their repeated observations (Dodds & Rivory, 1999) . Therefore, it is conceivable that in vitro assays, carried out on puri®ed preparations of AChE extracted from various sources, do not oer sucient levels of reliability to allow a clear assessment of the putative anti-AChE properties of irinotecan. For instance, while in their letter Dodds and Rivory emphasize the fact that the incubation time of irinotecan with AChE must be kept as close as possible to zero, at a temperature of 258C, to avoid spontaneous degradation of the drug, Morton et al. (1999) allowed an incubation time of 22 h at 378C, which is much longer than that adopted in our study (20 min).
We wish also to point out that, beyond the debate concerning the in vitro eects of irinotecan on AChE activity, several lines of evidence, emerging from the variety of experimental models adopted in our study (Blandizzi et al., 2001) , as well as from previous clinical reports (Gandia et al., 1993; Rowinsky et al., 1994) , argue against the hypothesis that AChE blockade plays a signi®cant role in the acute cholinergic syndrome evoked by irinotecan. In particular, the following points are worthy to be considered:
(1) At variance with physostigmine (0.01 ± 0.1 mM), irinotecan (tested up to 100 mM) did not signi®cantly aect the atropine-sensitive motor responses induced by electrical stimulation of human colonic longitudinal muscle (Blandizzi et al., 2001) . (2) Irinotecan moderately enhanced the cholinergic twitch contractions of guinea-pig ileum longitudinal muscle strips only when applied at very high concentrations (Blandizzi et al., 2001) . Of interest, in this model there is no need for long pre-incubation time, and changes in motor activity of ileal smooth muscle can usually be recorded immediately after spiking the test drugs into the organ bath solution.
(3) The measurement of electrically-induced acetylcholine release, from longitudinal muscle strips of guinea-pig ileum, represents a highly suitable technique in studies aiming to characterize the in¯uence of drugs on synaptic cholinergic neurotransmission. When tested on this model, irinotecan (up to 100 mM) slightly inhibited acetylcholine release, whereas, as expected, physostigmine (0.1 mM) caused a marked decrease through an indirect activation of muscarinic autoreceptors located on cholinergic axon terminals (Blandizzi et al., 2001) . (4) In the clinical setting, we could not detect any signi®cant inhibition of AChE activity in the blood of colorectal cancer patients subjected to treatment with irinotecan (Blandizzi et al., 2000) . In this study, irinotecan was infused at the dose of 200 ± 350 mg/m 2 over 60 min, and whole blood samples were taken immediately before (baseline) as well as 15 and 45 min after the beginning of drug infusion. Interestingly, similar data have been reported also by Gandia et al. (1993) , who measured AChE activity in erythrocytes isolated from cancer patients under infusion with irinotecan. (5) When examining the features of the acute syndrome evoked by irinotecan (Gandia et al., 1993; Rowinsky et al., 1994) , it can be noted that all symptoms are consistent with a picture of parasympathetic activation, leading to the recruitment of muscarinic receptors on peripheral eector organs. However, drugs causing a systemic blockade of AChE are expected also to promote a concomitant activation of nicotinic receptors, with the subsequent occurrence of symptoms, like for instance altered patterns of skeletal muscle motor activity, that have not been observed in patients treated with irinotecan (Gandia et al., 1993; Rowinsky et al., 1994) .
In conclusion, much work remains to be done, at experimental level, to clarify the dierences of Dodds and Rivory (1999) data on irinotecan-induced inhibition of AChE, compared with our results. However, in order to better elucidate the pathophysiological mechanisms which subserve the cholinergic side eects of irinotecan, we do not believe that in vitro pharmacological assays of AChE can be regarded as critical tests until they are uncon®rmed on functional basis by means of more integrated methodological procedures.
